tradmap

BCAX Earnings Bicara Therapeutics Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$90 -$45 $0 2023 2024 2025
EPS
Net income (annual)
-$138M -$69M $0 2023 2024 2025
Net income
Return on equity (annual)
-34% 0% 35% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$70 -$35 $0 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$56M -$28M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-12% 2% 17% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–12 of 12
Q2 20262026-06-30-1.732026-08-1110-Q
Q1 20262026-03-31-0.932026-05-1110-Q
FY 20252025-12-31-2.522026-03-3010-K
Q3 20252025-09-30-1.842025-11-1010-Q
Q2 20262025-06-30-1.182026-08-1110-Q
Q1 20262025-03-31-0.682026-05-1110-Q
FY 20252024-12-31-4.052026-03-3010-K
Q3 20252024-09-30-11.272025-11-1010-Q
Q2 20252024-06-30-38.192025-08-1210-Q
Q1 20252024-03-31-18.942025-05-1310-Q
FY 20242023-12-31-89.612025-03-2710-K
Q3 20242023-09-30-70.182024-11-1210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.